Biotechnology Gilead’s Aggressive Push Beyond HIV Treatments – Plans To Increase Cancer-Focused CAR-T Treatment Production – Gilead Sciences (NASDAQ:GILD) Read more
Biotechnology Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead’s and Merck’s Combo Therapy – Merck & Co (NYSE:MRK), Gilead Sciences (NASDAQ:GILD) Read more